Neonc technologies holdings, inc.NTHI.US Overview

US StockHealthcare

(No presentation for NTHI)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

NTHI Overall Performance

NTHI AI Analysis & Strategy

NTHI Recent Performance

-3.52%

Neonc technologies holdings, inc.

0.81%

Avg of Sector

-1.14%

S&P500

NTHI PowerScanner

NTHI Key Information

NTHI Valuation Metrics

NTHI Earnings Table

NTHI Profile

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.